scholarly journals Differences in Bone Mineral Density and Hip Geometry in Trochanteric and Cervical Hip Fractures in Elderly Chinese Patients

2019 ◽  
Vol 11 (2) ◽  
pp. 263-269 ◽  
Author(s):  
Ming Li ◽  
Hou‐chen Lv ◽  
Jian‐heng Liu ◽  
Xiang Cui ◽  
Guo‐fei Sun ◽  
...  
Keyword(s):  
Bone Mineral Density ◽  
Bone Mineral ◽  
Hip Fractures ◽  
Chinese Patients ◽  
Mineral Density ◽  
Hip Geometry ◽  
Elderly Chinese

The Clinical Use of Denosumab for the Management of Low Bone Mineral Density in Postmenopausal Women

2012 ◽  
Vol 25 (3) ◽  
pp. 310-318 ◽  
Author(s):  
Kira B. Harris ◽  
Kimberly L. Nealy ◽  
Delilah J. Jackson ◽  
Phillip L. Thornton
Keyword(s):  
Bone Mineral Density ◽  
Postmenopausal Women ◽  
Bone Mineral ◽  
Hip Fractures ◽  
Nuclear Factor Κb ◽  
Bisphosphonate Therapy ◽  
Mineral Density ◽  
Osteoporosis Therapy ◽  
Cost Of Health Care ◽  
Therapy Studies

Osteoporosis is a leading cause of debility and declining quality of life in postmenopausal women worldwide. Treatment of osteoporosis has been ubiquitous throughout the developed world since the mid-1990s, most notably with the introduction of bisphosphonates in 1995. Nonetheless, the incidence of hip fractures increased by 25% between 1990 and 2000, despite advances in osteoporosis therapy. Studies indicate that bone density increases over the first 3 years of bisphosphonate therapy and then plateaus or perhaps even declines, placing these patients at greater risk of fracture. Since hip fractures are associated with increased morbidity, mortality, and increased cost of health care, improvements in treating osteoporosis are critical. Denosumab is a novel monoclonal antibody targeted against the receptor activator of nuclear factor-κB ligand (RANKL) that inhibits osteoclast activity. Initial data suggest that denosumab increases bone mineral density for greater than 3 years. Of greater importance, denosumab has been shown to decrease vertebral fractures by 68%, nonvertebral fractures by 19%, and hip fractures by 42% for at least 36 months. Data also indicate that the safety profile of denosumab is equivalent to other drugs used in osteoporosis management, but potential risks of immunosuppression and cancer have been hypothesized.

scholarly journals Hip fractures following denosumab discontinuation: three clinical cases reports

2019 ◽  
Vol 112 (11) ◽  
pp. 472-475 ◽  
Author(s):  
Manuel Sosa Henríquez ◽  
María Jesús Gómez de Tejada Romero ◽  
María Escudero-Socorro ◽  
Oscar Torregrosa Suau
Keyword(s):  
Bone Mineral Density ◽  
Bone Mineral ◽  
Hip Fractures ◽  
Vertebral Fractures ◽  
Femoral Fractures ◽  
Significant Loss ◽  
Mineral Density ◽  
Denosumab Treatment ◽  
Multiple Vertebral Fractures ◽  
Clinical Cases

Summary A significant loss of bone mineral density and the appearance of multiple vertebral fractures after discontinuation of denosumab treatment have been described. To date, no hip fractures have been reported. We present three cases of patients who suffered femoral fractures after denosumab suppression.

Hip fractures and femoral bone mineral density in male former elite athletes

Bone ◽  
2010 ◽  
Vol 46 (2) ◽  
pp. 330-335 ◽  
Author(s):  
Jyrki A. Kettunen ◽  
Olli Impivaara ◽  
Urho M. Kujala ◽  
Miika Linna ◽  
Juhani Mäki ◽  
...  
Keyword(s):  
Bone Mineral Density ◽  
Bone Mineral ◽  
Hip Fractures ◽  
Elite Athletes ◽  
Femoral Bone ◽  
Mineral Density ◽  
Femoral Bone Mineral Density ◽  
Former Elite Athletes

Correlates of Bone Mineral Density in Elderly Patients with Hip Fractures

1995 ◽  
Vol 9 (6) ◽  
pp. 470-475 ◽  
Author(s):  
Douglas R. Dirschl ◽  
Richard C. Henderson ◽  
Ward S. Oakley
Keyword(s):  
Bone Mineral Density ◽  
Elderly Patients ◽  
Bone Mineral ◽  
Hip Fractures ◽  
Mineral Density
Sign in / Sign up

Export Citation Format

Share Document